Marginal zone lymphoma is a slow-growing type of blood cancer that affects white blood cells in the immune system. Treatment decisions depend on the disease subtype, the organs involved, and whether symptoms are present, with approaches ranging from watchful waiting to antibiotics, chemotherapy, immunotherapy, and targeted drugs under investigation in clinical trials.

How Doctors Approach Treatment for Marginal Zone Lymphoma

When someone receives a diagnosis of marginal zone lymphoma, the journey toward treatment begins with careful consideration of many factors. Because this disease grows slowly, doctors focus on controlling symptoms, slowing disease progression, and improving quality of life rather than rushing into aggressive therapy.^[1] The treatment plan is highly individualized and depends on which subtype of marginal zone lymphoma is present, where the disease has spread, and how the patient is feeling overall.

Medical societies have established standard treatments that have proven effective over many years of clinical experience. At the same time, researchers continue to explore new therapies through clinical trials, testing innovative drugs and approaches that may one day become part of routine care.^[7] For many patients, especially those without symptoms, treatment may not start immediately. Instead, doctors may recommend a strategy called watchful waiting, where the disease is monitored closely through regular checkups and tests, with treatment beginning only if symptoms develop or the disease progresses.^[7]

The three main types of marginal zone lymphoma—extranodal (often called MALT lymphoma), nodal, and splenic—each require different treatment considerations. Extranodal marginal zone lymphoma most commonly develops in the stomach but can appear in the lungs, skin, thyroid, salivary glands, or near the eyes.^[4] Nodal marginal zone lymphoma affects the lymph nodes and can spread to the bone marrow, while splenic marginal zone lymphoma primarily involves the spleen, blood, and bone marrow.^[2]

Standard Treatments Used in Clinical Practice

The most distinctive feature of marginal zone lymphoma treatment is that certain subtypes can be cured by addressing underlying infections. This is particularly true for gastric MALT lymphoma, the most common form of extranodal marginal zone lymphoma. Many cases of gastric MALT lymphoma are linked to a bacterial infection called Helicobacter pylori, or H. pylori, which lives in the stomach lining and causes chronic inflammation.^[7] When this infection is present, the initial treatment involves antibiotics combined with medications called proton pump inhibitors, which reduce stomach acid production and help prevent or heal ulcers.

This antibiotic treatment typically lasts for two weeks. In approximately 90 percent of cases, the lymphoma disappears following this treatment, although it may take several months for the cancer to fully resolve.^[7] This remarkable response demonstrates how eliminating the trigger that drives the immune system can allow the lymphoma to regress. Similarly, antibiotics like doxycycline have shown effectiveness in MALT lymphoma affecting the area around the eye, known as ocular adnexal lymphoma, which has been associated with certain infections.^[7]

If the lymphoma does not respond to antibiotic therapy, or if it returns after initial treatment, doctors turn to other options. For non-gastric MALT lymphoma, treatment depends heavily on where the disease is located and how far it has spread. When the lymphoma is confined to one area, radiation therapy may be used to target and destroy the cancer cells.^[7] For certain sites like the lung or breast, surgery might be considered to remove the affected tissue.

When the disease is more widespread, or when symptoms require intervention, doctors typically use a combination of immunotherapy and chemotherapy. Rituximab, sold under the brand name Rituxan, is an immunotherapy drug that targets a protein called CD20 found on the surface of B cells, the type of white blood cell affected by marginal zone lymphoma.^[7] Rituximab can be given alone or combined with chemotherapy drugs to enhance its effectiveness.

Common chemotherapy regimens include bendamustine plus rituximab, or a combination known as R-CHOP, which stands for rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.^[7] These treatments are also used for other slow-growing lymphomas, such as follicular lymphoma. The duration of treatment varies depending on the specific drugs used and how well the patient responds, but typically involves multiple cycles administered over several months.

For nodal marginal zone lymphoma, which affects the lymph nodes, and splenic marginal zone lymphoma, which primarily involves the spleen, treatment approaches differ slightly. Because nodal marginal zone lymphoma is often slow-growing, doctors may adopt an active surveillance approach, monitoring the patient without immediate treatment.^[7] When treatment becomes necessary, rituximab alone or combined with chemotherapy is commonly used. Some patients with splenic marginal zone lymphoma linked to hepatitis C infection may benefit from antiviral treatment targeting the hepatitis C virus.^[4]

In cases where the spleen is significantly enlarged and causing symptoms such as fatigue or abdominal discomfort, doctors may recommend surgical removal of the spleen, a procedure called splenectomy. This can provide symptom relief and, in some cases, lead to improvement in blood counts and overall disease control.^[1]

Treatment with chemotherapy and immunotherapy can cause side effects that vary depending on the specific drugs used. Common side effects of rituximab include reactions during the infusion, such as dizziness, low blood pressure, rapid heart rate, and numbness or tingling.^[15] These reactions are usually manageable, and oncology nurses are experienced in controlling them so patients can complete their treatment. Chemotherapy drugs may cause fatigue, nausea, hair loss, increased risk of infection due to low white blood cell counts, and other effects depending on the specific agents used.

Innovative Therapies Being Tested in Clinical Trials

While standard treatments have proven effective for many patients with marginal zone lymphoma, researchers continue to search for new and better therapies through clinical trials. These studies test promising drugs and treatment approaches that may eventually become part of routine care. Clinical trials are conducted in phases, each designed to answer specific questions about a new treatment.

Phase I trials focus primarily on safety, determining the appropriate dose and identifying potential side effects in a small group of patients. Phase II trials expand the study to more patients to evaluate how well the treatment works and to further assess safety. Phase III trials involve large numbers of patients and compare the new treatment directly with current standard therapies to determine if it offers advantages in effectiveness or safety.^[7]

One area of active research involves developing more targeted therapies that specifically attack cancer cells while sparing healthy tissue. Scientists are studying drugs that interfere with molecular pathways critical for lymphoma cell survival and growth. For example, some investigational drugs target specific enzymes or receptors on the surface of cancer cells, blocking signals that tell the cells to multiply or avoid death.

Immunotherapy approaches beyond rituximab are also being explored. Researchers are investigating whether newer antibodies or combinations of immunotherapy drugs can improve outcomes for patients with marginal zone lymphoma. Some studies are testing drugs that enhance the immune system’s ability to recognize and destroy cancer cells by targeting immune checkpoints, proteins that normally help regulate immune responses but can be hijacked by cancer cells to evade detection.

Clinical trials for marginal zone lymphoma are being conducted at major cancer centers in the United States, Europe, and other parts of the world.^[7] Eligibility for these trials depends on factors such as the patient’s specific subtype of marginal zone lymphoma, previous treatments received, overall health status, and the presence or absence of certain molecular markers. Patients interested in participating in clinical trials should discuss this option with their oncologist, who can help identify appropriate studies and determine if enrollment might be beneficial.

Preliminary results from some clinical trials have shown encouraging signs, including improvements in disease control, reduction in symptoms, and favorable safety profiles. However, it is important to remember that experimental treatments are still being studied, and their long-term benefits and risks are not yet fully understood. Participation in a clinical trial offers access to cutting-edge therapies and contributes valuable information that helps advance treatment for all patients with marginal zone lymphoma.

Supportive Care and Follow-Up

Beyond treatments directly targeting the lymphoma, supportive care plays a vital role in helping patients maintain their quality of life. This includes managing symptoms such as pain, fatigue, and nausea, as well as addressing the emotional and psychological challenges that come with a cancer diagnosis. Many cancer centers offer comprehensive support services, including counseling, nutrition guidance, and complementary therapies like acupuncture or massage.

After completing treatment, patients enter a follow-up phase where they are monitored regularly for signs of disease recurrence. Follow-up visits typically include physical examinations, blood tests, and periodic imaging studies to assess whether the lymphoma remains in remission or has returned.^[7] The frequency of these visits depends on the patient’s initial disease characteristics, the type of treatment received, and individual risk factors.

For patients who experience a relapse, meaning the lymphoma returns after a period of remission, or whose disease is refractory, meaning it does not respond to initial treatment, additional therapy options are available. These may include different combinations of chemotherapy and immunotherapy, more intensive treatments such as bone marrow transplant (also called stem cell transplant), or enrollment in clinical trials testing novel therapies.^[1]

Most common treatment methods

• Antibiotic therapy
  • Used primarily for gastric MALT lymphoma associated with H. pylori infection, typically combined with proton pump inhibitors for two weeks
  • Achieves lymphoma regression in approximately 90 percent of gastric MALT cases, though complete response may take several months
  • Doxycycline has shown effectiveness in ocular adnexal lymphoma associated with certain infections
• Immunotherapy with rituximab
  • Targets CD20 protein on the surface of B lymphocytes
  • Can be administered alone or in combination with chemotherapy
  • Common infusion-related side effects include dizziness, low blood pressure, rapid heart rate, and numbness
• Chemotherapy combinations
  • Bendamustine plus rituximab is a common regimen for more advanced disease
  • R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is another widely used combination
  • Duration typically involves multiple cycles administered over several months
• Radiation therapy
  • Used for localized disease, particularly non-gastric MALT lymphoma confined to one area
  • Targets and destroys cancer cells with minimal damage to surrounding tissue
• Surgery
  • May be considered for certain sites such as lung or breast to remove affected tissue
  • Splenectomy (removal of the spleen) can provide symptom relief in splenic marginal zone lymphoma
• Watchful waiting (active surveillance)
  • Appropriate for patients without symptoms, particularly with slow-growing disease
  • Involves regular monitoring through checkups, blood tests, and imaging studies
  • Treatment begins only if symptoms develop or disease progresses
• Bone marrow transplant
  • Also called stem cell transplant, may be considered for relapsed or refractory disease
  • Represents a more intensive treatment option when other therapies have not been successful
• Experimental therapies in clinical trials
  • Targeted drugs that interfere with molecular pathways critical for lymphoma cell survival
  • Novel immunotherapy approaches beyond rituximab, including immune checkpoint inhibitors
  • Tested in Phase I, II, and III trials at cancer centers worldwide